ProShares Ultra Bitcoin ETF vs GSK plc — how do they compare? ProShares Ultra Bitcoin ETF trades at $9.16, while GSK plc trades at $50.13 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while ProShares Ultra Bitcoin ETF pays none, and GSK plc is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BITU | GSK | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $64.41 | $61.18 |
52-Week Low | $8.12 | $38.22 |
Market Cap | — | $102.60B |
Enterprise Value | — | $123.04B |
Dividend Yield | — | 3.57% |
Signals from Pluang's Aura AI — not financial advice
BITU's stock trades at $9.205, down 1.34% in the last 24 hours, with a bearish technical signal from moving averages and a neutral stance from oscillators. The company has declared several dividends in 2026, with the latest being $0.02 per share. Key support and resistance levels are tightly clustered around $9 to $10, indicating limited recent price movement.
The outlook for BITU is cautious due to bearish technical indicators and negative sentiment from financial media. Investment opportunities may exist for dividend-focused investors, but risks include potential underperformance highlighted by analysts and market volatility. The stock's proximity to support levels suggests vulnerability to further declines.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →